What happened with ANIX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Anixa Biosciences is an early-stage biotechnology company with no revenue from its cancer programs and no other recurring revenue. Its lira-cel treatment modifies immune cells to target ovarian cancer and is in clinical development with Moffitt. It also develops cancer vaccines using technology licensed from Cleveland Clinic; its breast cancer vaccine is in clinical development, while its ovarian cancer vaccine remains preclinical.
The intended paying customers are pharmaceutical companies that would license its technologies and handle manufacturing, marketing and sales—capabilities Anixa lacks. Such agreements are not assured and may depend on positive human trial results. Earlier revenue came from patent licensing and technology sales, including litigation settlements; that legacy activity is now limited and is not expected to be a significant ongoing business.
Anixa depends on collaborators to run studies and trials, and on continued access to licenses from Wistar for its cell therapy and Cleveland Clinic for its vaccines. Losing those rights could restrict development or commercialization. Its candidates need regulatory approval before they can be marketed, and continued development depends on cash reserves and access to additional funding.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Anixa's prospects depend on clinical results from its Moffitt-developed ovarian CAR-T therapy and Cleveland Clinic-licensed cancer vaccines, continued access to Wistar and Cleveland Clinic intellectual property, and eventual licensing deals with pharmaceutical companies.
Precigen's PRGN-3005 competes with Anixa's lira-cel: both are developing cell therapies to treat ovarian cancer, a program that has not yet generated revenue for Anixa. Precigen has paused PRGN-3005 enrollment, so watch whether it resumes recruiting patients into that trial.
Regeneron is developing ovarian-cancer cell therapies that compete with Anixa's lira-cel, though they are only a small part of Regeneron's broader medicine-development and sales business. For Anixa holders, watch Regeneron's ovarian cell-therapy progress rather than its EYLEA and EYLEA HD sales.
Fed Interest Rate Decision
Anixa Biosciences earns interest on its cash and short-term investments, so Fed rate decisions can change the income it receives as those investments mature and are reinvested.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can lift the interest Anixa earns when short-term investments mature and are reinvested, adding income to help fund its cancer-vaccine and CAR-T research.
If it comes in below expectations
Lower rates can reduce the interest Anixa earns when short-term investments mature and are reinvested, leaving less income to help fund its cancer-vaccine and CAR-T research.
Precigen, Inc. earningsPGEN
Precigen's report may show whether it has resumed recruiting patients for PRGN-3005, revealing whether competition with Anixa's lira-cel is intensifying.
Look for whether PRGN-3005 has resumed recruiting and whether its trial is moving forward. If recruitment restarts, Precigen is again advancing an ovarian-cancer cell therapy that competes with lira-cel, making the competitive pressure on Anixa more immediate. If recruitment remains paused, that pressure is lower for now, but it does not show that lira-cel works.
Anixa Biosciences, Inc. earningsThis company
Anixa has no revenue from its therapies or vaccines, so this report shows whether its cash use is moving its programs forward.
Read research and development spending alongside cash used in operations, then check for progress in lira-cel and the cancer-vaccine programs. Progress with manageable cash use would show limited funds advancing the research; falling cash without clear progress would make funding a more immediate constraint, and raising money by issuing shares could dilute existing owners.
